Iov-Com-202- A Phase 2, Multicenter Study Of Autologous Tumor Infiltrating Lymphocytes (Ln 144/Ln-145/Ln-145-S1) In Patients With Solid Tumors
Posted Date: Nov 28, 2020
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Oncology
- Type of Study: Drug
This is a prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with pembrolizumab or TIL LN-145/LN-145-S1 as a single therapy. The primary outcome measured for this study is Objective response rate.
Criteria:
To Be Eligible: Must Have Confirmed Diagnosis Of Malignancy Of Their Receptive Histologies: Unresectable Or Metastatic Melanoma Stage Iiic/Iv, Advanced Recurrent Or Metastatic Hnscc, Or Stage Iii/Iv Nsclc, Ecog 0-1, Life Expectancy >6 Months, No Active Il
Keywords:
Advanced Solid Tumors
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com